Targets › ESR2
29 programs from 28 companies in 35 trials: 16 Phase 2, 9 Phase 4, 7 Phase 3, 3 Phase 1; Oncology, Genitourinary, Psychiatry; next expected readout Dec 2026.
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner..; FUNCTION: [Isoform 2]: Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability. (UniProt, Q92731)
Open in Phaseline: the race on ESR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, San Francisco | Hormone Replacement Therapy (HRT) Estrogen and progestin replacement | ESR1, ESR2, PGR | Phase 4 | Adhesive Capsulitis of the Shoulder | Dec 2026 |
| The Alfred | Bazedoxifene Acetate Selective estrogen receptor modulator (SERM) | ESR1, ESR2 | Phase 4 | Schizophrenia | Dec 2026 |
| Mackay Memorial Hospital | Conjugated equine estrogen (Premarin) Estrogen receptor agonist (vaginal cream formulation) | ESR1, ESR2 | Phase 4 | Effect of Drug | Dec 2026 |
| Insel Gruppe AG, University Hospital Bern | Hormone Replacement Therapy (HRT) Transdermal estradiol and oral micronized progesterone replacement | ESR1, ESR2, PGR | Phase 4 | Insomnia | Jan 2027 |
| University of California, Irvine | Estring Vaginal Product Estradiol released locally from a vaginal ring | ESR1, ESR2 | Phase 4 | Recurrent Urinary Tract Infection | Jun 2027 |
| Andrew Zakhari | Estetrol Estrogen receptor agonist | ESR2, ESR1 | Phase 4 | Ovarian Endometrioma | Jul 2027 |
| Penn State University | Combined Oral Contraceptive (COC) / Apri (Reclipsen) Oral ethinyl estradiol-based contraceptive; estrogen receptor agonist | ESR1, ESR2, PGR | Phase 4 | Other Disorders of Bone Development and Growth | Dec 2028 |
| LeonaBio | Lasofoxifene Estrogen receptor modulator | ESR2, ESR1 | Phase 3 | Metastatic Breast Cancer | Apr 2027 |
| Wen Tianfu | Chlorotrianisene Estrogen receptor beta modulator | ESR2 | Phase 3 | Advanced Hepatocellular Carcinoma | May 2027 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Chlorotrianisene Estrogen receptor beta modulator | ESR2 | Phase 3 | Hepatocellular Carcinoma | Jun 2027 |
| Sarah Wozney | Conjugated Estrogens CSD Estrogen receptor agonist | ESR1, ESR2 | Phase 3 | Pelvic Organ Prolapse (POP) | Sep 2027 |
| Assistance Publique - Hôpitaux de Paris | Estrogens (ESTREVA® 0.1% gel or PROVAMES® 1 mg) Estrogen receptor agonist | ESR1, ESR2 | Phase 3 | Gender Dysphoria | Jun 2029 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Estrogens, Conjugated Estrogen receptor agonist | ESR2, ESR1 | Phase 3 | Premature Ovarian Insufficiency | Dec 2031 |
| Hatice Tukenmez Kurnaz | Estriol Estrogen receptor modulator | ESR2, ESR1 | Phase 3 | Pelvic Organ Prolapse | – |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Raloxifene Estrogen receptor beta modulator; Estrogen receptor modulator | ESR2, ESR1 | Phase 2 | Breast Cancer; BPH (Benign Prostatic Hyperplasia); Brain Tumor | Dec 2026 |
| Tianjin Medical University Cancer Institute and Hospital | Toremifene Estrogen receptor modulator | ESR2, ESR1 | Phase 2 | CANCER | Dec 2026 |
| Azure Biotech | Lasofoxifene Tartrate (AZU-101) Estrogen receptor modulator | ESR2, ESR1 | Phase 2 | Vulvo Vaginal Atrophy (VVA) | Dec 2026 |
| University of Southern California | bazedoxifene / conjugated estrogens Tissue selective estrogen complex (TSEC) | ESR1, ESR2 | Phase 2 | Atherosclerosis | Dec 2026 |
| Roberta Brinton | PhytoSERM Phytoestrogen supplement containing genistein, daidzein, and S-equol | ESR1, ESR2 | Phase 2 | Menopause | Jan 2027 |
| UNC Lineberger Comprehensive Cancer Center | toremifene Estrogen receptor modulator | ESR2, ESR1 | Phase 2 | Breast Cancer | Apr 2027 |
| University of Kansas Medical Center | Bazedoxifene and Conjugated Estrogens Selective estrogen receptor modulator (SERM) plus estrogen hormone replacement therapy | ESR1, ESR2 | Phase 2 | Risk Reduction | Jul 2027 |
| Nutrindo Ideais Research Center | OESTROGEL Transdermal estradiol; estrogen receptor agonist | ESR1, ESR2 | Phase 2 | Menopause | Oct 2027 |
| Nutrindo Ideais Research Center | PENTRAVAN Transdermal estradiol delivery system; estrogen receptor agonist | ESR1, ESR2 | Phase 2 | Menopause | Oct 2027 |
| Fred Hutchinson Cancer Center | Transdermal Estrogen Estrogen receptor agonist | ESR1, ESR2 | Phase 2 | Castration-Sensitive Prostate Adenocarcinoma | Jun 2029 |
| University of Virginia | transdermal 17β-E2 with cyclic progestin Estrogen receptor agonist with cyclic progestin | ESR1, ESR2, PGR | Phase 2 | Bone Strength | Dec 2029 |
| Northwestern University | Afimoxifene Estrogen receptor modulator; Estrogen-related receptor gamma antagonist | ESR2, ESR1, ESRRG | Phase 2 | Cancer Survivor | – |
| University of Pennsylvania | Estrogens, Conjugated Estrogen receptor agonist | ESR2, ESR1 | Phase 1 | Ischemia Reperfusion Injury | Jan 2027 |
| St. Joseph's Healthcare Hamilton | Duavive (conjugated estrogens/bazedoxifene) Estrogen receptor agonist with selective estrogen receptor modulator component | ESR1, ESR2 | Phase 1 | Menopause | – |
| University of Oxford | Menopausal hormone therapy (systemic, oestrogen-containing) Oestrogen receptor agonist | ESR1, ESR2 | Phase 1 | Menopause | – |
Menopause (5) Bone Strength (3) Breast Cancer (2) Recurrent Urinary Tract Infection (2) Other Disorders of Bone Development and Growth (2) Pelvic Organ Prolapse (POP) (1) Hepatocellular Carcinoma (1) BPH (Benign Prostatic Hyperplasia) (1) Brain Tumor (1) Risk Reduction (1) Premature Ovarian Insufficiency (1) Pelvic Organ Prolapse (1)
small molecule (24), antibody (1), mixed (1)
Nutrindo Ideais Research Center (2) Sarah Wozney (1) London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) University of Kansas Medical Center (1) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) St. Joseph's Healthcare Hamilton (1) Hatice Tukenmez Kurnaz (1) Wen Tianfu (1) Andrew Zakhari (1) The Alfred (1) Northwestern University (1) Mackay Memorial Hospital (1) University of Oxford (1) University of California, San Francisco (1) University of Virginia (1) University of California, Irvine (1) Roberta Brinton (1) Fred Hutchinson Cancer Center (1) University of Pennsylvania (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.